angiogenin and Lymphoma--B-Cell

We report on the generation and functional characterization of a humanized immunoenzyme comprising a stable humanized single chain Fv (scFv) with grafted specificity of the anti-CD22 murine monoclonal antibody RFB4 and the human ribonuclease angiogenin (ANG). The fusion protein produced from transiently transfected mammalian Chinese hamster ovary cells could easily be purified to homogeneity, retained full ribonucleolytic activity, and efficiently killed CD22(+) tumour cells with an IC(50) of 56 nmol/l. In contrast, incubation of tumour cells with either ANG or scFv alone did not result in any cytotoxicity. Potent receptor-mediated killing of target cells, expected lack of extracellular toxicity, predictable low immunogenic potential, and ease of production, suggest that this novel immunoenzyme has potential for the immunotherapy of CD22(+) malignancies.

Topics: Animals; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Cell Adhesion Molecules; Cell Line, Tumor; CHO Cells; Cricetinae; Cytotoxicity Tests, Immunologic; Genetic Engineering; Humans; Immunization, Passive; Immunoglobulin Fragments; Lectins; Lymphoma, B-Cell; Recombinant Fusion Proteins; Ribonuclease, Pancreatic; Sialic Acid Binding Ig-like Lectin 2; Transfection